Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SKV-07
- Development stage
- Unknown
- Lead developer
- West China Hospital of Sichuan University
- Modality
- Oncolytic Viruses → Oncolytic Therapeutics, Gene Therapies
- Administration
- Intravitreal
01
Overview
SKV-07 is an investigational oncolytic virus therapy developed by West China Hospital of Sichuan University for the treatment of uveal melanoma. Administered via intravitreal or onocular injection, SKV-07 is designed to selectively replicate within and destroy malignant cells in the eye while potentially inducing a localized and systemic anti-tumor immune response. It is currently undergoing a Phase 1, single-arm, dose-escalation clinical trial in China (ChiCTR2600124673) to evaluate its safety, tolerability, viral shedding, and preliminary antitumor activity in patients with locally advanced or radiotherapy-refractory uveal melanoma.
Beyond the preview
Go deeper on SKV-07.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SKV-07.